In the Specification:

At page 1, before the "Background of the Invention," please insert the following paragraph:

Related Applications

This application is the National Stage of PCT/US94/09024, filed August 5, 1994 (published in English), which claims benefit of US application number 08/106016, filed August 13, 1993. The entire contents of the above-referenced applications are incorporated herein by reference.

Please replace the paragraph at page 2, lines 32-34, as follows:

Fig. 1A and Fig. 1B shows the nucleotide sequence of cDNA clone 12R (SEQ ID NO:1) and its predicted amino acid sequence (SEQ ID NO:2). Clone 12R is a full-length clone of Lol p V derived from a λgtII library (see PCT application publication number WO93/04174).

Please replace the paragraph at page 4, lines 11-13, as follows:

Fig. 16A, Fig. 16B, and Fig. 16C show ~~shows~~ the nucleotide sequence of clone 259 of Dac g V, and its predicted amino acid sequence, the nucleotide sequence of nucleotides 1 to 699 has been confirmed, and the nucleotide sequence of nucleotides 700 to 1181 are unconfirmed.

Please replace the paragraph at page 35, lines 9-17, as follows:

Balb/c mice were immunized with crude *Dactylis glomerata* (orchard grass/cocksfoot grass) pollen extract and antibody secreting clones were generated as described (Walsh *et al.*, *Int. Arch. Allergy Appl. Immunol.*, 1990, **91**: 419-425). MAb 1B9 hybridoma clone which cross-reacts to Lol p V was obtained from Dr. Walker (Univ. Birmingham, Wolfson Research Lab, Birmingham, UK). Ascitis fluid generated from Balb/c mice was produced by contract (Babco, Richmond, CA). The antibodies were purified from ascites fluid by $(NH_4)_2 SO_4$ precipitation (50% saturation). The pellet was resuspended in 10mM phosphate buffer, pH 7.5 and dialyzed against the same buffer at 4°C overnight and then fractionated by ion-exchange chromatography on FPLC ~~Q-Sepharose~~ Q-SEPHAROSE column (Pharmacia, Piscataway, NJ) using linear gradient 0-0.5 M NaCl. IgG was eluted between 0.15-0.2 M NaCl concentration.

Please replace the paragraph at page 35, lines 21-26, as follows:

Purified 1B9 was coupled to ~~Affigel 10~~ AFFIGEL-10 resin (Biorad, Richmond, CA) using 3-4 mg protein/mL of gel according to manufacturer's instructions. In brief, PFLC ~~Q-Sepharose~~ Q-SEPHAROSE column purified mAb 1B9 was dialyzed against 0.1M MOPS buffer, pH 7.5 with two to three changes overnight at 4°C. The ~~Affigel 10~~ AFFIGEL-10 resin was washed with deionized cold H_2O in a scintered glass funnel. The washed resin was mixed with the 1B9 antibody for four hours at 4°C, followed by an one-hour blocking step with 1 M ethanolamine, pH 8.0. Resin was packed into a column, washed with PBS and than stored in PBS + 0.05% sodium azide.

Please replace the paragraph at page 36, lines 6-10, as follows:

The unbound materials were loaded onto the 1B9-~~Affigel 10~~ AFFIGEL-10 column at a flow rate of 0.5ml/min. The column was then washed extensively with PBS, PBS + 0.5 NaCl and once again with PBS before elution of the *Lol p* V allergens with 0.1 M glycine, pH 2.7. Fractions were neutralized with 1 M Tris, pH 11.0 immediately. These affinity-purified materials were used in IgE studies and T cell epitope mapping.

Please replace the Table at page 37, lines 9-13, as follows:

amino acid #	1	11
Lol p V (SEQ ID NO:54)	A D A G Y T P' A A A A T P' A T P' A A T P'	
	21	31
	A A A G G K A T T D E Q K	